This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Leverage first-party data to refine retargeting strategies while maintaining HIPAA compliance. FDA and HIPAA Compliance in PPC Fair balance requirements Ads must include benefits and risks equally. No unapproved drug claims All claims must be backed by clinical research and FDA-approved labeling.
As automation becomes smarter, ensuring HIPAA and GDPR compliance remains critical. Leveraging tools that enable real-time content approval and centralized tracking can prevent outdated messaging or off-label promotion. However, marketers must balance innovation with privacy.
The emergence of HIPAA-compliant targeting technologies, HCP-specific segments, and improved analytics has made social platforms not just viable but essential for pharmaceutical marketing. While off-label promotion is still strictly regulated, unbranded awareness campaigns have found creative footing. It’s a strategic pillar.
Challenges in Pharma Email Marketing Pharma brands face unique barriers that other industries dont , such as: Strict compliance regulations (FDA, GDPR, HIPAA) that limit messaging. Drug names and indications must align with FDA-approved labeling. Email fatigue among HCPs and patients , leading to low open rates.
Enhance Dialogue-Based Engagement Clarify Required Disclosures Allow HIPAA Waivers if Feasible Clarify Speaker Selection Process Allow for Data Submissions After Sessions Increase Engagement. Off-label usage often emerges from real- world clinical practice and patient experiences, which might not be reflected in the guidelines.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content